Tag Archives: Drugs for Vulvovaginal Candidiasis

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug AdministrationContinue reading “Global Drugs for Vulvovaginal Candidiasis Market Research: Key Companies Profile with Sales, Revenue, Price and Competitive Situation Analysis”

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug AdministrationContinue reading “Global Drugs for Vulvovaginal Candidiasis Industry Report: Overview with Product Scope, Opportunities Risk, Market Driving Force”